JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

2.45 -6.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.41

Максимум

2.56

Ключови измерители
By Trading Economics
Служители	26

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+461.8% upside

Дивиденти
By Dow Jones
Следващи печалби	6.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-71K 20M
Предишно отваряне	9.29
Предишно затваряне	2.45

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.11.2025 г., 23:57 ч. UTC

Печалби

Naver's Third-Quarter Earnings Rose on AI Push

4.11.2025 г., 23:10 ч. UTC

Придобивния, сливания и поглъщания

Kennedy-Wilson Gets Acquisition Proposal From CEO, Fairfax Financial

4.11.2025 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.11.2025 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Fall After U.S. Tech Stock Weakness -- Market Talk

4.11.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Technical Recovery -- Market Talk

4.11.2025 г., 23:30 ч. UTC

Печалби

Itau Unibanco 3Q Net BRL33.7B >ITUB

4.11.2025 г., 23:25 ч. UTC

Печалби

Naver 3Q Net Profit Beat FactSet-Compiled Consensus

4.11.2025 г., 23:25 ч. UTC

Печалби

Naver 3Q Net KRW734.70B Vs. Net KRW530.10B >035420.SE

4.11.2025 г., 23:24 ч. UTC

Печалби

Naver 3Q Oper Pft KRW570.60B Vs. Pft KRW525.30B >035420.SE

4.11.2025 г., 23:23 ч. UTC

Печалби

Naver 3Q Rev KRW3.138T Vs. KRW2.716T >035420.SE

4.11.2025 г., 23:06 ч. UTC

Печалби

Review & Preview: Tech Check -- Barrons.com

4.11.2025 г., 22:52 ч. UTC

Печалби

AMD Reports Sharply Higher Profits, Sales -- 3rd Update

4.11.2025 г., 22:33 ч. UTC

Печалби

AMD Beats Earnings. The Stock Still Slides. -- Barrons.com

4.11.2025 г., 22:29 ч. UTC

Печалби

Ashland 4Q Adj EPS $1.08 >ASH

4.11.2025 г., 22:29 ч. UTC

Печалби

Ashland Sees FY26 Adjusted EPS Up More Than Double Digits >ASH

4.11.2025 г., 22:28 ч. UTC

Печалби

Ashland Sees FY26 Sales $1.84B-$1.91B >ASH

4.11.2025 г., 22:27 ч. UTC

Печалби

Ashland 4Q Cont Ops EPS 73c >ASH

4.11.2025 г., 22:27 ч. UTC

Печалби

Ashland 4Q EPS 71c >ASH

4.11.2025 г., 22:27 ч. UTC

Печалби

Ashland 4Q Sales $478M >ASH

4.11.2025 г., 22:23 ч. UTC

Печалби

Ovintiv 3Q EPS 57c >OVV

4.11.2025 г., 22:19 ч. UTC

Пазарно говорене

Canada Budget: Snap Election Talk Might Cool -- Market Talk

4.11.2025 г., 22:16 ч. UTC

Печалби

AMD Reports Sharply Higher Profits, Sales -- 2nd Update

4.11.2025 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

Kennedy-Wilson Board Forms Special Committee to Evaluate Proposal

4.11.2025 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Consortium: Not Interested in Selling Kennedy-Wilson Shares to Another Party

4.11.2025 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Consortium: Able to Finance a Deal With Available Liquidity

4.11.2025 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Consortium Owns About 31% of Kennedy-Wilson Stock on As-Converted Basis

4.11.2025 г., 22:11 ч. UTC

Печалби

Private-Credit Earnings Ease Investor Concern Over Market's Health -- Update

4.11.2025 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

Kennedy-Wilson Gets Proposal From CEO William McMorrow and Fairfax Financial Holdings

4.11.2025 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4.11.2025 г., 22:07 ч. UTC

Печалби

Kinross Gold Raises Dividend to $0.035 >K.T

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Ценова цел

By TipRanks

461.8% нагоре

12-месечна прогноза

Среден 15 USD 461.8%

Висок 15 USD

Нисък 15 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Lisata Therapeutics през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.